Novartis agreed to pay $125 million for the Sironax blood-brain barrier crossing platform, obtaining global rights to technology intended to transport multiple drug modalities into the central nervous system. The deal is positioned as a way to support neuroscience programs as Novartis navigates setbacks in its neuro pipeline. The platform acquisition follows a recurring industry challenge: delivering large therapeutic molecules across the BBB with sufficient target engagement and safety. Novartis is expected to leverage the technology across multiple candidates, with Sironax describing the approach as having “best-in-class” potential. For biotech partners and rivals, the transaction underscores that BBB delivery capabilities—particularly modality-agnostic platforms—remain a strategic priority for Big Pharma when late-stage neuroscience efforts stall.